Amgen & Watson Sign for Oncology Biosimilars

Under the terms of the agreement, Amgen will assume primary responsibility for developing, manufacturing and initially commercializing the oncology antibody products.

Amgen and Watson Pharmaceuticals, Inc. announced Monday that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines.

This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients.

Under the terms of the agreement, Amgen will assume primary responsibility for developing, manufacturing and initially commercializing the oncology antibody products. 

Watson will contribu